Pineal Melatonin Functions: Possible Relevance to Parkinson's Disease

References

• Agid Y., Javoy-Agid F. Peptides and Parkinson's disease. Trends in Neurosciences 1985; 8: 30–35
   Web of Science ®Google Scholar
• Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. lnternational Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Anton Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Google Scholar
• Anton-Tay F. The pineal-brain relationship. The pineal gland, G. E. W. Wolstenholme, J. Knight. Churchill Livingstone, London 1971; 231–220
   Google Scholar
• Anton-Tay F., Chou C., Anton S., Wurtman R. J. Brain serotonin concentrations: elevation following intraperitoneal administration of melatonin. Science 1968; 162: 277–278
   PubMed Web of Science ®Google Scholar
• Appenzeller O. O., Goss J. E. Autonomic deficits in Parkinson's disease. Archives of Neurology 1971; 24: 50–57
   PubMedGoogle Scholar
• Apps M. C. P., Sheaff P. C., Ingram D. A., Kennardn C., Empey D. W. Respiration and sleep in Parkinson's disease. Jouranl of Neurology Neurosurgery and Psychiatry 1985; 48: 1240–1245
   PubMed Web of Science ®Google Scholar
• Axelrod J., Shein H. M., Wurtman R. 3. Stimulation of c24-melatonin synthesis from c14 tryptophan by noradrenaline in rat pineal in organ culture. Proceedings of the National Academy of Science, USA 1969; 62: 544–549
   PubMed Web of Science ®Google Scholar
• Barbeau A. Parkinson's disease: Etiological considerations. The basal panglia, M. D. Yahr. Raven Press, New York 1976; 281–292
   Google Scholar
• Barbeau A. Role of peptides in the pathogenesis and treatment of Parkinson's disease. Central nervous system effects of hypothalamic hormones and other peptides, R. Collu. Raven Press, New York 1979; 403–414
   Google Scholar
• Barbeau A., Pourcher E. New data on the genetics of Parkinson's disease. Canadian Journal of Neurological Sciences 1982; 9: 53–60
   PubMed Web of Science ®Google Scholar
• Barker R. A., Cahn A. P. Parkinson's disease: An autoimmune process. International Journal of Neuroscience 1988; 43: 1–7
   PubMed Web of Science ®Google Scholar
• Birau N., Alexander D., Berthholdt S., Meyer C. Low nocturnal melatonin serum concentrations in anorexia nervosa—further evidence for body weight influence. IRCS Medical Science 1984; 12: 477–480
   Google Scholar
• Birkeland A. J. Plasma melatonin levels and nocturnal transitions between sleep and wakefulness. Neuroendocrinology 1982; 34: 126–131
   PubMed Web of Science ®Google Scholar
• Blask D. E. The pineal: An oncostatic gland?. The pineal gland, R. J. Reiter. Raven Press, New York 1984; 253–284
   Google Scholar
• Blask D. E., Hill S. M. Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. Journal of Neural Transmission 1986; 21((suppl))433–449
   Google Scholar
• Blask D. E., Nodelman J. L., Leadem C. A. Preliminary evidence that a dopamine receptor antagonist blocks the prolactin-inhibitory effects of melatonin in anosmic male rats. Experientia 1980; 36: 1008–1009
   PubMedGoogle Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the midbrain can regulate forebrain dopamine function both behaviourally and biochemically. The pineal gland: Endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Brambilla F., Fraschini F., Esposti G., Bossolo P. A., Marelli G., Ferrari E. Melatonin circadian rhythm in anorexia nervosa and obesity. Psychiatry Research 1988; 23: 267–276
   PubMed Web of Science ®Google Scholar
• Brown R., Kocsis J. H., Caroff S., Amsterdam J., Winokur A., Stokes P. E., Frazer A. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. American Journal of Psychiatry 1985; 142: 811–816
   PubMed Web of Science ®Google Scholar
• Brown E., Brown G. M., Kofman O., Quarrington B. Sexual function and affect in parkinsonian men treated with L-dopa. American Journal of Psychiatry 1978; 135: 1552–1555
   PubMed Web of Science ®Google Scholar
• Cantello R., Aguggia M., Gilli M., Delsedime M., Riccio A., Rainero I., Mutani R. Analgesic action of rnethylphenidate on Parkinsonian sensory symptoms. Archives of Neurology 1988; 45: 973–976
   PubMedGoogle Scholar
• Cantello R., Gilli M., Riccio A., Bergamasco B. Modd changes associated with “end-of-dose deterioration” in Parkinson's disease: a controlled study. Journal of Neurology Neurosurgery and Psychiatry 1986; 49: 1182–1190
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movements induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Van Woert M. H., Schiffer L. Aromatic amino acids and modifications of parkinsonism. New England Journal of Medicine 1967; 276: 374–379
   PubMed Web of Science ®Google Scholar
• Cremer-Bartels G., Ebels I., Sykes J. E. C., de Moree A. Effects of retinal and pineal low molecular weight fractions and antipsychotic drugs on hydroxyindole-O-methyltransferase. Journal of Neural Transmission 1983; 58: 107–119
   PubMed Web of Science ®Google Scholar
• Datta P. C., King M. G. Effects of melanocyte-stimulating hormone (MSH) and melatonin on passive avoidance and on an emotional response. Pharmacology Biochemistry and Behavior 1977; 6: 449–452
   PubMedGoogle Scholar
• Datta P. C., King M. G. Melatonin: effects on brain and behavior. Neuroscience & Biobehavioral Reviews 1978; 4: 451–458
   Web of Science ®Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Demaine C., Kann H. C. Hypothalamic neurones as possible target cells for pineal indoles. Journal of Physiology 1979; 291: 49P–50P
   Google Scholar
• Den Hartog J. W. A., Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. Journal of Neurology Neurosurgery and Psychiatry 1960; 23: 283–290
   PubMedGoogle Scholar
• Diaz B., Blatquez E. Effect of pinealectomy on plasma glucose, insulin and glucagon levels in the rat. Hormone Metabolism Research 1986; 18: 225–229
   PubMed Web of Science ®Google Scholar
• Donohue T. L., Dorsa D. M. The opiomelanotrophinergic neuronal and endocrine system. Peptides 1982; 3: 353–395
   PubMedGoogle Scholar
• Dray A. Serotonin in the basal ganglia: Functions and interactions with other neuronal pathways. Journal of Physiology (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Dubocovich M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782–784
   PubMed Web of Science ®Google Scholar
• Eisler T., Thorner M. O., McLeod R. M., Kaiser D. L., Calne D. B. Prolactin secretion in Parkinson's disease. Neurology 1981; 31: 1356–1359
   PubMedGoogle Scholar
• Erlich S. S., Apuzzo M. L. J. The pineal gland: Anatomy, physiology, and clinical significance. Journal of Neurosurgery 1985; 63: 321–341
   PubMed Web of Science ®Google Scholar
• Fahn S., Snider S. R., Prasad A. L. N., Lane E., Makadon H. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats. Neurology 1975; 25: 861–865
   PubMed Web of Science ®Google Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Foley P. B., Cairncross K. D., Folders A. Pineal indoles: Significance and measurement. Neuroscience & Biobehavioral Reviews 1986; 10: 273–293
   PubMed Web of Science ®Google Scholar
• Fujimura H., Umbach I. Role de l'atteinte de la substance reticulee dans la demence de la maladie de Parkinson. Revue Neurologique, (Paris) 1987; 143: 108–114
   PubMed Web of Science ®Google Scholar
• Gehlen W., Muller J. Zur Therapie der Dopa-Psychosen mit L-tryptophan. Deutsche Medizinische Wochenschrift 1974; 99: 457–463
   Web of Science ®Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29((suppl))553
   Google Scholar
• Goetz C. G., Luthe W., Tanner C. M. Autonomic dysfunction in Parkinson's disease. Neurology 1986; 36: 73–75
   PubMed Web of Science ®Google Scholar
• Govitrapong P., Murrin L. C., Ebadi M. Characterization of dopaminergic receptor sites in bovine pineal gland. Journal of Pineal Research 1984; I: 215–226
   Google Scholar
• Gubbay S. S., Barwick D. D. Two cases of accidental hypothermia in Parkinson's disease with unusual EEG findings. Journal of Neurology Neurosurgery and Psychiatry 1966; 29: 459–466
   PubMed Web of Science ®Google Scholar
• Hansen T., Bikeland A. J., Lingjaerde O. Melatonin ands sleep in man: A preliminary report. Sleep research, R. G. Priest, A. Pletscher, J. Ward. University Park Press, Baltimore 1978; 43–44
   Google Scholar
• Hariharasubramanian N., Nair N. P. V., Pilapil C. Circadian rhythm of plasma melatonin and cortisol during the menstrual cycle. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 31–36
   Google Scholar
• Hartley R., Padwick D., Smith J. A. The inhibition of pineal hydroxyindole-O-methyltransferase by haloperidol fluphenazine. Journal of Pharmacology and Pharmacy 1972; 24((suppl.))100P–103P
   Google Scholar
• Henderson V. W., Wooten G. F. Neuroleptic-malignant syndrome: A pathogenetic role for dopamine receptor blockade?. Neurology 1981; 31: 132–137
   PubMed Web of Science ®Google Scholar
• Hutchison V. H., Black J. J., Erskine D. Melatonin and chlorpromazine: thermal selection in the mudpuppy, nectus maculosus. Life Sciences 1979; 25: 527–530
   PubMedGoogle Scholar
• Jansson B., Jankovic J. Low cancer rates among patients with Parkinson's disease. Annals of Neurology 1985; 17: 505–509
   PubMedGoogle Scholar
• Jouvet M. The role of monoamines and acetycholine containing neurons in the regulation of the sleep waking cycle. Review of Physiology and Biochemical Pharmacology 1972; 64: 166–307
   Google Scholar
• Kales A., Anael R. D., Markham C. H., Dcharf M. B., Tan T. L. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration. Clinical Pharmacology and Therapeutics 1971; 4: 397–406
   Google Scholar
• Kane J. M., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988; 8((suppl))52S–56S
   Google Scholar
• Kastin A. J., Redding T. W., Schally A. V. MSH activity in rat pituitaries after pinealectomy. Proceedings of the Society of Experimental Biology and Medicine 1967; 124: 1275–1277
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Viosca S., Nair R. M. G., Schally A. V., Miller M. C. Interactions between pineal, hypothalamus and pituitary involving melatonin, MSH release-inhibiting factor and MSH. Endocrinology 1972; 91: 1323–1328
   PubMed Web of Science ®Google Scholar
• Kavaliers M. Pineal mediation of the thermoregulatory and behavioral activating effects of beta-endorphin. Peptides 1982; 3: 679–685
   PubMed Web of Science ®Google Scholar
• Kavaliers M., Hirst M., Teskey G. C. Ageing, opioid analgesia and the pineal gland. Life Sciences 1983; 32: 2279–2287
   PubMed Web of Science ®Google Scholar
• Kendel K., Beck U., Wita C., Hohneck E., Zimmerman H. Der Einfluss von L dopa auf den Nachtschlaf bei patienten mit Parkinson-Syndrom. Archives Psychiatry und Nervenkrankheilen 1972; 216: 82–100
   PubMedGoogle Scholar
• Keshaven M. S., David A. S., Narayanen H. S., Satish P. “on-off” phenomena and manic-depressive mood shifts: case report. Journal of Clinical Psychiatry 1986; 47: 93–94
   PubMedGoogle Scholar
• Klein D. C. The pineal gland: A model of neuroendocrine regulation. The hypothalamus, S. Reichlin, R. J. Baldessarini, J. B. Martin. Raven Press, New York 1978; 303–327
   Google Scholar
• Klein D. C. The pineal gland: A model of neuroendocrine regulation. The hypothalamus, S. Reichlin, R. J. Baldessarini, J. B. Martin. Raven Press, New York 1978; 303–327
   Google Scholar
• Klein D. C., Smoot R., Weller J. L., Higa S., Markey S. P., Creede G. J., Jacobowitz D. M. Lesions of the paraventricular nucleus area of the hypothalamus disrupt the suprachiasmatic-spinal cord circuit in the melatonin rhythm generating system. Brain Research Bulletin 1983; 10: 647–652
   PubMed Web of Science ®Google Scholar
• Koller W. C. Sensory symptoms in Parkinson's disease. Neurology 1984; 34: 957–959
   PubMed Web of Science ®Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Korczyn A. Dementia in Parkinson's disease. Alzheimer's and Parkinson's disease: Strategies for research and development, A. Fisher, I. Hanin, C. Lachman. Plenum Press, New York 1986; 177–183
   Google Scholar
• Kovacs G. L., Gajari I., Telegdy G., Lissak K. Effect of melatonin and pinealectomy on avoidance and exploratory activity in the rat. Physiology and Behavior 1974; 13: 349–355
   PubMed Web of Science ®Google Scholar
• Kumar M. S. A., Besch E. L., Millard W. J., Sharp D. C., Leadem C. A. Effect of short photoperiod on hypothalamic methionine-enkephalin and LHRH content on serum beta-endorphin-like immunoreactivity (beta-end LI) levels in golden hamsters. Journal of Pineal Research 1984; I: 197–205
   Google Scholar
• Lakin M. L., Miller C. H., Statt M. L., Winters W. D. Involvement of the pineal gland and melatonin in murine analgesia. Life Sciences 1981; 29: 2543–2551
   PubMed Web of Science ®Google Scholar
• Langston J. W., Forno L. S. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
   PubMed Web of Science ®Google Scholar
• Lawton N. G., MacDermot J. Abnormal regulation of prolactin release in idiopathic Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1980; 43: 1012–1015
   PubMedGoogle Scholar
• Lehmann J. Tryptophan malabsorption in levodopa-treated parkinsonian patients: effect of tryptophan on mental disturbances. Acta Medica Scandinavica 1973; 194: 181–189
   PubMedGoogle Scholar
• Leong A. S. Y., Matthews C. D. The pineal gland as an APUD organ: supporting evidence and implications. Medical Hypothesis 1979; 5: 265–273
   PubMedGoogle Scholar
• Lewinski A. Evidence for pineal gland inhibition of thyroid growth contribution to the hypothesis of a negative feedback between the thyroid and the pineal. Advances in pineal research, R. J. Reiter, M. Karasek. John Libbey. 1986; 167–176
   Google Scholar
• Lewy A. J., Nurnberg J. I., Wehr T. A., Pack D., Becker L. E., Powell R. L., Newsome D. A. Supersensitivity to Light: Possible trait marker for manic-depressive illness. American Journal of Psychiatry 1985; 142: 725–727
   PubMed Web of Science ®Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Disease 1974; 27: 573–579
   PubMedGoogle Scholar
• Lissoni P., Esposti D., Esposti G., Mauri R., Resentini M., Morabito F., fu Magali P., Santagostino A., Delitala G., Fraschini F. A clinical study on the relationship between the pineal gland and the opioid system. Journal of Neural Transmission 1986; 65: 63–73
   PubMed Web of Science ®Google Scholar
• Lynch H. J., Wang P., Wurtman R. J. Increase in rat pineal melatonin content following L-dopa administration. Life Sciences 1973; 12: 145–151
   Web of Science ®Google Scholar
• Malarkey W. B., Cyrus J. W., Paulson G. W. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. Journal of Clinical Endocrinology and Metabolism 1974; 314: 229–235
   Google Scholar
• Marczynski T. J., Yamaguchi N., Ling G. M. Sleep induced by the administration of melatonin (5-methoxy-N-acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia 1964; 20: 435–437
   PubMedGoogle Scholar
• Marsden C. D., Parkes J. D. “on-off” effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; I: 292–296
   Google Scholar
• Maurizi C. P. A mechanism of mania and the chemistry of dreams: A hypothesis. Southern Medical Journal 1984; 77: 1491–1493
   PubMed Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L. J. The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• Miles A., Philbrick D. R. S. Melatonin in psychiatry. Biological Psychiatry 1988; 23: 405–425
   PubMed Web of Science ®Google Scholar
• Miles A., Philbrick D. R. S., Shaw D. M., Tidmarsh S. F., Pugh A. J. Salivary melatonin estimation in clinical research. Clinical Chemistry 1985; 31: 2041–2042
   PubMed Web of Science ®Google Scholar
• Miller E. M., Nieburg H. A. L-tryptophan in the treatment of levodopa induced psychiatric disorders. Diseases of the Nervous System 1974; 35: 20–23
   PubMedGoogle Scholar
• Mindham R. H. S. Psychiatric symptoms in parkinsonism. Journal of Neurology Neurosurgery and Psychiatry 1970; 33: 188–189
   PubMed Web of Science ®Google Scholar
• Mouret J., Coindet J., Chouvet G. Effect of pinealectomy on sleep stages in rhythms of the male rat. Brain Research 1974; 81: 97–105
   PubMedGoogle Scholar
• Nair N. P. V., Hariharasubramanian N., Pilapil C., Isaac I., Thavundayil J. X. Plasma melatonin—an index of brain aging in humans?. Biological Psychiatry 1986a; 21: 141–150
   PubMed Web of Science ®Google Scholar
• Nair N. P.V., Hariharasubramanian N., Pilapil N., Thavunday J. X. Plasma melatonin rhythm in normal aging and Alzheimer's disease. Journal of Neural Transmission 1986b; 21((suppl))494
   Google Scholar
• Namboodiri M. A. A., Sugden D., Klein D. C., Mefford I. N. 5-hydroxytryptophan elevates serum melatonin. Science 1983; 221: 659–660
   PubMed Web of Science ®Google Scholar
• Nappi G., Petraglia F., Martignoni E., Facchineti F., Bono G., Genazzani A. R. Beta-endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 1985; 35: 1371–1374
   PubMed Web of Science ®Google Scholar
• Nausieda P. A., Tanner C. M., Klawans H. L. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Advances in neurology: experimental therapeutics of movement disorders, S. Fahn, D. B. Calne, I. Shoulson. Raven Press., New York 1983; 23–32
   Google Scholar
• Nausieda P. A., Weiner W. J., Kaplan L. R., Weber S., Klawans H. L. Sleep disruption in the course of chronic levodopa therapy: An early feature of the levodopa psychosis. Clinical Neuropharmacology 1982; 5: 183–194
   PubMed Web of Science ®Google Scholar
• Naylor R. J., Olley J. E. The distribution of haloperidol in rat brain. British Journal of Pharmacology 1969; 36: 208P–209P
   Web of Science ®Google Scholar
• Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the “on-off” phenomenon in Parkinson's disease. Psychological Medicine 1987; 17: 899–904
   PubMed Web of Science ®Google Scholar
• Pang S. F., Tang F., Tang P. L. Alloxan-induced diabetes and the pineal gland: Differential effects on the levels of pineal N-acetylserotonin, pineal melatonin, and serum melatonin. Journal of Pineal Research 1985; 2: 79–84
   PubMed Web of Science ®Google Scholar
• Papavasiliou P. S., Cotzias G. C., Duby S. E., Steck A. J., Bell M., Lawrence W. H. Melatonin and Parkinsonism. Journal of the American Medical Association 1972; 221: 88–89
   PubMed Web of Science ®Google Scholar
• Paterson A. T., Rickerby J., Simpson J., Vickers C. Possible interaction of melanocyte-stimulating hormone (MSH) and the pineal in the control of territorial aggression in mice. Physiology & Behavior 1980; 24: 843–848
   PubMed Web of Science ®Google Scholar
• Pearce A. G. E. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. Journal of Histochemistry and Cytochemistry 1969; 17: 303–313
   PubMedGoogle Scholar
• Pearce A. C. E. Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proceedings of the Royal Society of Biology 1968; 170: 11–76
   Google Scholar
• Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton J. P. Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Quinn N. P., Marsden C. D. Menstrual-related fluctuations in Parkinson's disease. Movement Disorders 1985; 1: 85–87
   Google Scholar
• Rainero I., Kaye J. A., May C., Durso R., Katz D. I., Albert M. I., Wolfe N., Pinessi L., Friedland R. P., Rapoport S. I. Alpha-melanocyte-stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 1988; 45: 1224–1227
   PubMedGoogle Scholar
• Reiter R. J. Neuroendocrine effects of the pineal gland and of melatonin. Frontiers in neuroendocrinology, W. F. Ganong, L. Martini. Raven Press, New York 1982; 287–301
   Google Scholar
• Reiter R. J., Richardson B. A., Johnson L. Y., Ferguson B. N., Dinh D. T. Pineal melatonin rhythm: reducing in aging Syrian hamsters. Science 1980; 210: 1372–1373
   PubMed Web of Science ®Google Scholar
• Rosenberg P., Herishanu Y., Beilin B. Increased appetite (bulimia) in Parkinson's disease. Journu1 of the American Geriatrics Society 1977; 25: 277–278
   PubMedGoogle Scholar
• Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
   PubMed Web of Science ®Google Scholar
• Sack R. L., Lewy A. J., Erb D. L., Vollmer W. M., Singer C. M. Human melatonin production decreases with age. Journal of Pineal Research 1986; 3: 379–388
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. Hypothalamic-mediated immune mechanisms and their relevance to Parkinson's disease. International Journal of Neuroscience 1987; 32: 979–981
   PubMed Web of Science ®Google Scholar
• Sandyk R., lacono R. P. Neuroleptic malignant syndrome. Journal of the American Medical Association 1986; 255: 2291
   Google Scholar
• Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. International Journal of Neuroscience 1989; 45: 119–122
   PubMed Web of Science ®Google Scholar
• Sandyk R. Melatonin, sex steroids, and opioid peptide interactions in Tardive dyskinesia. International Journal of Neuroscience 1989, (in press a)
   Google Scholar
• Sandyk R. Pineal melatonin functions and the depression of Parkinson's disease. International Journal of Neuroscience, (in press b)
   Google Scholar
• Sandyk R. The protective Function of the Pineal Gland in Tardive-Dyskinesia. International Journal of Neuroscience 1988; 43: 215–218
   PubMed Web of Science ®Google Scholar
• Sandyk R. Locus coeruleus-pineal melatonin interactions and the pathogenesis of the “on-off” phenomenon associated with mood changes and sensory symptoms in Parkinson's disease. International Journal of Neuroscience, (in press c)
   Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience, (in press)
   Google Scholar
• Sandyk R., Iacono R. P. The relationship of the reticular system to the primary pathoetiology of Parkinson's disease. International Journal of Neuroscience 1988; 42: 297–300
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P., Bamford C. R. The hypothalamus in Parkinson disease. Italian Journal of Neurological Science 1987; 8: 227–234
   PubMedGoogle Scholar
• Sandyk R., Iacono R. P., Bamford C. R. Spinal cord mechanisms in amitriptyline responsive restless legs syndrome in Parkinson's disease. International Journal of Neuroscience 1988; 38: 121–124
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia. Journal of Clinical Psychopharmacology 1989; 9: 147–148
   PubMed Web of Science ®Google Scholar
• Sandyk R., Mukherjee S. Attenuation of reserpine-induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience, (in press).
   Google Scholar
• Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–1133
   PubMed Web of Science ®Google Scholar
• Scatton B., Dennis T., L'heureux R. Degeneration of noradrenergic and serotonergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Shaw K. M. Hypothalamo-pituitary adrenal function in Parkinsonian patients treated with melatonin. Current Medical Research Opinion 1977; 4: 743–746
   Web of Science ®Google Scholar
• Shaw K. M., Stern G. M., Sandler M. Melatonin and metatyrosine in the treatment of parkinsonism. Advances in neurology, D. B. Calne. Raven Press, New York 1973; 115–119
   Google Scholar
• Shaw K. M., Stern G. M., Sandler M. Melatonin and Parkinsonism. Lancet 1973; I: 271–272
   Google Scholar
• Shuster S., Burton J. L., Thody A. J., Goollamali S. K., Burton J. L., Plummer N., Bates D. Melanocyt—stimulating hormone and Parkinsonism. Lancet 1973; I: 463–465
   Google Scholar
• Silman R. E., Leone R. M., Hooper R. J. L., Preece M. A. Melatonin, the pineal gland and human puberty. Nature 1979; 282: 301–303
   PubMed Web of Science ®Google Scholar
• Smythe G. A., Lazarus L. Growth hormone responses to melatonin in man. Science 1974; 184: 1373–1374
   PubMed Web of Science ®Google Scholar
• Snider S. R., Fahn S., Isgreen W. P., Cote L. J. Primary sensory symptoms in parkinsonism. Neurology 1976; 26: 423–429
   PubMed Web of Science ®Google Scholar
• Snider S. R., Sandyk R. Sensory dysfunction. Handbook of Parkinson's disease, W. C. Koller. Marcel Dekker, New York 1987; 171–180
   Google Scholar
• Souetre E., Salvati E., Belugou J. L., Robert P., Brunet G., Darcourt G. Antidepressant effect of 5-methoxypsoralen: A preliminary report. psychopharmacology 1988; 95: 430–431
   PubMed Web of Science ®Google Scholar
• Sugden D., Morris R. D. Changes in regional brain levels of tryptophan, 5-hydroxytryptamine, 5-hydroxyindoleacetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal of Neurochemistry 1979; 32: 1593–1594
   PubMed Web of Science ®Google Scholar
• Sugden D. Psychophamacological effects of melatonin in mouse and rat. Journal of Pharmacology and Experimental Therapeutics 1983; 227: 587–591
   PubMed Web of Science ®Google Scholar
• Szabadi E. Neuroleptic malignant syndrome. British Medical Journal 1934; 288: 1399–1400
   Google Scholar
• Tamarkin L., Abastillas P., Chen H. C., McNemar A., Sidbury J. B. The daily profile of plasma melatonin in obese and Prader-Willi syndrome children. Journal of Clinical Endocrinology and Metabolism 1982; 55: 491–496
   PubMedGoogle Scholar
• Tanner C. M. Drug-induced movement disorders (tardive dyskinesia and dopa-induced dyskinesia). Handbook of clinical neurology: extrapyramidal disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier, Amsterdam 1986; 185–204
   Google Scholar
• Tetsuo M., Polinsky R. J., Markey S. P., Kopin I. J. Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension. Journal of Clinical Endocrinology and Metabolism 1982; 53: 607–610
   Web of Science ®Google Scholar
• Tonna E. A. Accumulation of lipofuscin (age pigment) in aging skeletal connective tissues as revealed by electron microscopy. Journal of Gerontology 1975; 30: 3–8
   PubMedGoogle Scholar
• Torre E., Celis M. E., Chiocchio S. R. Alpha-MSH and Pro-Leu-Gly-NH2 (PLG; MIF-I): influence of dopamine (DA) uptake in crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP). Peptides 1984; 5: 669–674
   PubMed Web of Science ®Google Scholar
• Traczynska K. D., Atzef E., Quadens P. Le Sommeil dans la maladie de Parkinson. Acta Neurologica Belgica 1969; 69: 727–733
   Google Scholar
• Trentini G. P., De Gaetani C. F., Criscuolo M., Migaldi M., Ferrari G. Pineal calcifications in different physiopathological conditions in humans. Fundamentals and clinics in pineal research, G. P. Trentini, C. De Gaetani, P. Pevet. Raven Press, New York 1987; 291–304
   Google Scholar
• Van der Linden C., Jankovic J., Jansson B. Lateral hypothalamic dysfunction in Parkinson's disease. Annals of Neurology 1985; 18: 137–138
   Web of Science ®Google Scholar
• Vaughan G. M, McDonald S. D., Jordan R. M., Allen J. P., Bell R., Stevens E. A. Melatonin, pituitary functions and stress in humans. Psychoneuroendocrinology 1979; 4: 351–362
   PubMed Web of Science ®Google Scholar
• Vitte P. A., Harthe C., Lestage P., Claustrat B., Bobillier P. Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: A biochemical and autoradiographic study. Journal of Pineal Research 1988; 5: 437–453
   PubMed Web of Science ®Google Scholar
• Vriend J. Influence of the pineal gland and circadian rhythms in circulating levels of thyroid hormones of male hamsters. Journal of Pineal Research 1984; 1: 15–22
   PubMed Web of Science ®Google Scholar
• Waldhauser F., Weiszenbacher G., Frisch H., Zeithuber U., Waldhauser M., Wurtman R. J. Flal in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984; I: 362–365
   Google Scholar
• Webley G. E., Bohle A., Leidenberger F. A. Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men. Journal of Pineal Research 1988; 5: 19–33
   PubMedGoogle Scholar
• Wendel O. T., Waterbury L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 167–1168
   Google Scholar
• Weterberg L., Beck-Friis J., Aperia B., Petterson U. Melatonin/cortisol ratio in depression. Lancet 1979; 2: 1361
   Google Scholar
• Wetterberg L. The relationship between the pineal gland and the pituitary-adrenal axis in health, endocrine and psychiatric conditions. Psychoneuroendocrinology 1983; 8: 75–80
   PubMed Web of Science ®Google Scholar
• Wetterberg L., Arendt J., Paunier L., Sizonenko P. C., Van Donselaar W., Heyden T. Human serum melatonin changes during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 1976; 42: 185–188
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A., Arendt J., Marston A. Antidepressant drugs elevate rat pineal and plasma melatonin. Experientia 1980; 36: 442–444
   PubMedGoogle Scholar
• Wooton G. F. Neurochemistry. Handbook of Parkinson's disease, W. C. Koller. Marcel Dekker, New York 1987; 237–251
   Google Scholar
• Yassa R., Schwartz G. Depression as a predictor in the development of tardive dyskinesia. Biological Psychiatry 1984; 19: 441–444
   PubMedGoogle Scholar
• Zigmond M. J., Acheson A. L., Stachowiak M. K., Strickerm E. M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Archives of Neurology 1984; 41: 856–861
   PubMedGoogle Scholar
• Zisapel N., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Research 1983; 272: 378–381
   PubMed Web of Science ®Google Scholar